{"id":"lithium-plus-carbamazepine","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Polyuria and polydipsia"},{"rate":null,"effect":"Cognitive impairment"},{"rate":null,"effect":"Ataxia"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hyponatremia"}]},"_chembl":{"chemblId":"CHEMBL108","moleculeType":"Small molecule","molecularWeight":"236.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lithium affects second-messenger systems and reduces inositol levels, influencing serotonin and norepinephrine neurotransmission. Carbamazepine blocks voltage-gated sodium channels and has anticonvulsant properties that stabilize neuronal membranes. The combination is used in bipolar disorder to enhance mood stabilization through complementary mechanisms.","oneSentence":"Lithium and carbamazepine together modulate mood through distinct mechanisms: lithium alters intracellular signaling and neurotransmitter activity, while carbamazepine acts as a sodium channel blocker and anticonvulsant.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:35.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar disorder (acute and maintenance treatment)"},{"name":"Treatment-resistant bipolar depression"}]},"trialDetails":[{"nctId":"NCT06274255","phase":"","title":"Serum Magnesium Level and Pediatric Migraine","status":"UNKNOWN","sponsor":"Mersin University","startDate":"2024-03-01","conditions":"Migraine, Magnesium, Pediatric","enrollment":60},{"nctId":"NCT02870283","phase":"PHASE4","title":"Cost- Effectiveness and Quality of Life Assessment in Mood Disorder","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2010-05","conditions":"Bipolar Disorder","enrollment":107},{"nctId":"NCT00643123","phase":"PHASE4","title":"Allopurinol Add-on Treatment for Refractory Mania","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2007-09","conditions":"Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania","enrollment":40},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT00562861","phase":"PHASE2, PHASE3","title":"Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2007-11","conditions":"Bipolar Disorder, Bipolar Depression","enrollment":119},{"nctId":"NCT00976794","phase":"PHASE4","title":"Efficacy of Combined Treatment for Young Bipolar I Disorder","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-01","conditions":"Bipolar I Disorder","enrollment":40},{"nctId":"NCT00325286","phase":"PHASE4","title":"Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2006-05","conditions":"Bipolar Disorder","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"lithium plus carbamazepine","genericName":"lithium plus carbamazepine","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbamazepine is a small molecule that acts as a sodium channel alpha subunit blocker. It has been studied in combination with lithium for various conditions, including bipolar disorder and migraine, but the exact indications and outcomes are not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}